Cargando…
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients
The aim of the present study was to define the activity and tolerability of a triplet regimen including oxaliplatin 130 mg m(−2) (2 h i.v. infusion) and raltitrexed 3.0 mg m(−2) (15 min i.v. infusion) given on day 1, followed by levo-folinic acid 250 mg m(−2) (2 h i.v. infusion) and 5-fluorouracil 1...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375419/ https://www.ncbi.nlm.nih.gov/pubmed/12085178 http://dx.doi.org/10.1038/sj.bjc.6600414 |
Sumario: | The aim of the present study was to define the activity and tolerability of a triplet regimen including oxaliplatin 130 mg m(−2) (2 h i.v. infusion) and raltitrexed 3.0 mg m(−2) (15 min i.v. infusion) given on day 1, followed by levo-folinic acid 250 mg m(−2) (2 h i.v. infusion) and 5-fluorouracil 1050 mg m(−2) i.v. bolus on day 2, every 2 weeks, in pretreated colorectal cancer patients. From April 1999 to December 2000, 50 patients were enrolled: 26 were males and 24 females, their median age was 63 (range, 43–79) years; ECOG performance status was 0 in 26 patients, ⩾1 in 24 patients; 26 patients had received previous adjuvant chemotherapy, 40 patients had been exposed to one or two lines of palliative chemotherapy (including irinotecan in 31 cases); 18 patients were considered chemo-refractory. A total of 288 cycles were administered, with a median number of 6 (range 1–12) courses per patient. A complete response was obtained in three patients, and a partial response in nine patients, giving a major response rate of 24% (95% confidence interval, 13–38%), while 15 further patients showed a stable disease, for an overall control of tumour growth in 60% of patients. Three complete responses and three partial responses were obtained in patients pretreated with irinotecan (response rate, 19%); among refractory patients, three achieved partial responses (response rate, 13%). After a median follow-up of 18 (range, 10–30) months, 40 patients showed a progression of disease: the growth modulation index ranged between 0.2 and 2.5: it was ⩾1.33 (showing a significant delay of tumour growth) in 16 (40%) patients. Actuarial median progression-free survival time was 7.6 months, and median survival time was 13.6 months: estimated probability of survival was 55% at 1 year. Main severe toxicity was neutropenia: World Health Organisation grade 4 affected 32% of patients; non-haematological toxicity was mild: World Health Organisation grade 3 diarrhoea was complained of by 8%, and grade 3 stomatitis by 4% of patients; neurotoxicity (according to Lévi scale) was scored as grade 3 in 8% of patients. In conclusion, this regimen was manageable and active as salvage treatment of advanced colorectal cancer patients; it showed incomplete cross-resistance with irinotecan-based treatments, and proved to delay the progression of disease in a relevant proportion of treated patients. British Journal of Cancer (2002) 86, 1871–1875. doi:10.1038/sj.bjc.6600414 www.bjcancer.com © 2002 Cancer Research UK |
---|